{"id":"https://genegraph.clinicalgenome.org/r/c3c1e317-b7b5-41d1-b23c-ed9f793bc38cv2.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between GNMT and Glycine N-methyltransferase Deficiency (AR) was evaluated using\nthe ClinGen Clinical Validity Framework as of 03/29/19. Variants in GNMT were first reported in\nhumans with this disease as early as 2001 (Mudd et al., PMID: 11596649). At least four variants, mostly missense, have been reported in humans in three publications (Mudd et al., 2001; PMID: 11596649; BariÄ‡ et al., 2016; PMID: 27207470; Augoustides-Savvopoulou et al., 2003; PMID: 14739680). Patients with GNMT deficiency have elevated serum transaminases without other serious clinical symptoms.  Evidence supporting this gene-disease relationship includes case-level data and experimental data, including animal models and expression studies. In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Aminoacidopathy Working Group on 05/10/19 (SOP Version 6). It was reevaluated on 10/14/2022 with no new evidence found. As a result of this reevaluation, the classification remained Limited. ","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/c3c1e317-b7b5-41d1-b23c-ed9f793bc38c","GCISnapshot":"https://genegraph.clinicalgenome.org/r/cafb0200-f6cf-482d-9ffb-69ae7bc43669","calculatedEvidenceStrength":"Moderate","changes":[{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"},{"id":"cg:sopChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/cafb0200-f6cf-482d-9ffb-69ae7bc43669_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2022-12-12T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/cafb0200-f6cf-482d-9ffb-69ae7bc43669_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2022-12-16T15:52:07.941Z","role":"Publisher"}],"curationReasonDescription":"Despite the points technically placing this curation into the Moderate category, the amount of information gathered about this disorder is too small to uphold this classification. With more evidence, particularly genetic, this could be reconsidered.","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cafb0200-f6cf-482d-9ffb-69ae7bc43669_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cafb0200-f6cf-482d-9ffb-69ae7bc43669_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0dd30811-a576-4506-80e0-deb2e1515893","type":"EvidenceLine","dc:description":"The authors use both cirrhotic patients and controls to demonstrate the expression in the liver, with multiple other sources cited using supporting methionine metabolism literature. This level of evidence provides enough to earn a default score.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/417b117e-3bb9-4f04-adc7-9e93605270b2","type":"Finding","dc:description":"The authors took samples of both cirrhotic and normal livers and measured them for various enzymes involved in methionine metabolism, including GMNT. It was very low/undetectable in 54% of the cirrhotic samples, with the controls showing a significant increase in activity comparatively. Since the vast majority of phenotypes demonstrated by those with GNMT deficiency are in the liver, this demonstrates that the gene is expressed in the area of interest to the deficiency. It is also further noted that the expression is confined mainly to the liver in the introduction.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11131452","rdfs:label":"Expression of Liver Enzymes in Cirrhotic and Control Livers","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cafb0200-f6cf-482d-9ffb-69ae7bc43669_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/12db1609-e11d-48d3-b368-fa25c45bfc3b","type":"EvidenceLine","dc:description":"This model provides a well-researched and significant group of phenotypic similarities to the few known patients with GNMT deficiencies. The experiment receives a point increase to represent the rigor and amount of evidence provided.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7fa74706-7f35-4d96-8b30-4761d434ac5e","type":"Finding","dc:description":"The GMNT knockout mice match the phenotypes of GNMT deficency patients in several ways, most notably being the similar symptoms of hypermethioninemia, hepatomegaly, and elevated serum ALT. All of these are hallmarks of the few known patients with the deficiency. In addition, the mice shared several other phenotypes with patients of G6PT deficiencies such as decreased numbers of white blood cells and hypoglycemia. These mimic some of the phenotypes found in GNMT deficiency as well. Altogether, this model gives strong indications that the gene and disease are linked.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17937387","rdfs:label":"GNMT Knockout Mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/aaf5f36e-0ac4-4c9d-8c3c-94bc4c1cc063","type":"EvidenceLine","dc:description":"Although the model is well researched, there are few phenotypes established. Given that the hypermethioninemia plus the enzyme activity alone is a significant portion of the phenotype, but lacks any other information, this score has been downgraded accordingly.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d9c98c3-569c-4a6e-a661-fc30176f800d","type":"Finding","dc:description":"The most prevalent symptom of GNMT deficency is humans is hypermethioninemia, since GNMT is integral to the metabolism of methionine, and the knockout mice show a significant increase as well. This, coupled with the increase in SAM and the decrease in SAH levels, very closely mimics the phenotype described in the human patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16779654","rdfs:label":"GNMT Knockout Mice Generation","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.5},{"id":"https://genegraph.clinicalgenome.org/r/cafb0200-f6cf-482d-9ffb-69ae7bc43669_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/78bb6e3d-7e61-4ee0-8bbb-97340a135829_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/78bb6e3d-7e61-4ee0-8bbb-97340a135829","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11596649","rdfs:label":"Mudd et al. Case 1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":2,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/d9295b4c-6179-4888-9f4d-9a18b8722d0b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018960.6(GNMT):c.149T>C (p.Leu50Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4169"}},{"id":"https://genegraph.clinicalgenome.org/r/9b3e3a00-fa54-4e3f-8ca3-91b1ae55856b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018960.6(GNMT):c.529C>A (p.His177Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/4170"}}],"detectionMethod":"Genomic DNAs isolated from blood and fibroblast cell culture samples. Control DNA samples from 44 US individuals on the DNA Polymorphism Discovery Resource Panel, 33 non-related individual of the Centre d'Etude du Polymorphisme Humain panel, and 21 healthy Italian individuals. PCR amplification of genomic DNA by specific primers. DNA sequenced by dideoxy sequencing method and checked for matching by BLAST software. Mutations detected were confirmed by restriction analysis.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"PCR","phenotypeFreeText":"Birthweight 3060 g, SGOT at 11 mo 150 U/L, SGPT at 11 mo 160 U/L, updated to 96 U/L and 100 U/L at 1.8 y respectively (Reference for both <35), At 1.8 y plasma lactic acid (2.9 mmol/L; reference 2.5) was elevated and Serum folic acid (4.9 ng/ml; reference 3.1-12.4) and vitamin B12 (900 pg/ml; reference 223-1132) were normal, At 3.9 y alkaline phosphatase was elevated (928 U/L; reference 223-703), 4.7 y serum tricglycerides elevated (184 mg/dl; reference 30-154), fasting plasma methionine elevated (644 umol/L; reference 13-45). Increased urinary methionine excretion (40 umol/mmol creatinine; reference 5-21). Increased lactic acid excretion (107 umol/mmol creatinine). Mild centrilobular fibrosis in liver. Some eosinophils present in liver.","phenotypes":["obo:HP_0001508","obo:HP_0003128","obo:HP_0001395","obo:HP_0003648"],"previousTesting":true,"previousTestingDescription":"Amino acid assays; urinary organic acid analysis by gas chromatography- mass spectrometry; MAT II, MTHFR, AdoMet activity assay","secondTestingMethod":"Restriction digest","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/47150774-6d7a-431f-b6e9-be3af1b763cc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11596649","allele":{"id":"https://genegraph.clinicalgenome.org/r/9b3e3a00-fa54-4e3f-8ca3-91b1ae55856b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/0a853e42-2eef-4dea-86ee-602fc08d3d3c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11596649","allele":{"id":"https://genegraph.clinicalgenome.org/r/d9295b4c-6179-4888-9f4d-9a18b8722d0b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/47150774-6d7a-431f-b6e9-be3af1b763cc","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/47150774-6d7a-431f-b6e9-be3af1b763cc_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/0a853e42-2eef-4dea-86ee-602fc08d3d3c","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0a853e42-2eef-4dea-86ee-602fc08d3d3c_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/cafb0200-f6cf-482d-9ffb-69ae7bc43669_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd814439-02bf-4136-9e9d-e63199c0106f_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals to score the segregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11596649","rdfs:label":"Family 1","family":{"id":"https://genegraph.clinicalgenome.org/r/cd814439-02bf-4136-9e9d-e63199c0106f","type":"Family","rdfs:label":"Family 1","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/78bb6e3d-7e61-4ee0-8bbb-97340a135829"}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002910","obo:HP_0002240","obo:HP_0003235"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/78bb6e3d-7e61-4ee0-8bbb-97340a135829"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/d6258eeb-2ea4-4d19-b2ba-9c8610de3061_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d6258eeb-2ea4-4d19-b2ba-9c8610de3061","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14739680","rdfs:label":"Augoustides-Savvopoulou Case 1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d7b7913c-a4f6-4ebf-9293-496ea1a57a1b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018960.6(GNMT):c.422A>G (p.Asn141Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/218931"}},"detectionMethod":"Genomic DNA isolated from blood samples (affected patient and 10 healthy American controls). All exons, most introns, and ~300 nucleotides of the 5' and 3' flanking ends were purified and sequencing done by dideoxy sequencing method.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"PCR","phenotypeFreeText":"3350 g birthweight, mildly elevated ALT and AST at 2y, mild ferritin elevation (173 ng/ml; reference 13-150), elevated serum triglycerides (155 mg/dl; reference 40-144), elevated total cholesterol (248 mg/dl; reference 120-220), elevated aspartate transaminase (31 to 154 U/L; reference 10-34), elevated alanine transaminase (34-180 U/L; reference 7-33), elevated urine methionine (508-627 umol/L; reference 8-40), elevated methionine excretion (60 umol/mmol; reference 5-21), elevated plasma methionine (1005-1049 umol/L; reference 13-45), plasma AdoMet (1643-2222 nmol/L; reference 93 +/- 16), plasma cystathionine (740-900 nmol/L; reference 44-342), plasma phosphatidylcholine (2622-2641 umol/L; reference 1500-2559), plasma betaine (218-382 umol/L; reference 26-67), plasma dimethylglycine (11.7-12.1 umol/L; reference 1.4-5.3)","phenotypes":["obo:HP_0003281","obo:HP_0002587","obo:HP_0008872","obo:HP_0001662","obo:HP_0003235","obo:HP_0002910"],"previousTesting":true,"previousTestingDescription":"Metabolite assays: tHcy- fluorescent polarization method; urinary organic acids- gas chromatography mass spectrometry; plasma methionine, tHcy, cystathionine, tCys, dimethylglycine, sarcosine- capillary gas chromatography","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/782d5423-f8c0-47e9-a1dc-c0247ebc4dfd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14739680","allele":{"id":"https://genegraph.clinicalgenome.org/r/d7b7913c-a4f6-4ebf-9293-496ea1a57a1b"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/782d5423-f8c0-47e9-a1dc-c0247ebc4dfd","type":"EvidenceLine","dc:description":"Although we have a good amount of phenotypic and variant-level information, the likelihood of the proband being consanguineous in their unknown parentage is too high considering his background and homozygosity. ","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/782d5423-f8c0-47e9-a1dc-c0247ebc4dfd_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/782d5423-f8c0-47e9-a1dc-c0247ebc4dfd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This variant was expressed in E. coli cells and showed <1% activity compared to wild-type.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ccc46a66-70ce-4e24-9521-5b80bb94471c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ccc46a66-70ce-4e24-9521-5b80bb94471c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27207470","rdfs:label":"Baric et al. Case 1","ageType":"AgeAtReport","ageUnit":"Months","ageValue":66,"allele":{"id":"https://genegraph.clinicalgenome.org/r/3f5e7726-0197-4d48-ad2b-1563916dff08","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018960.6(GNMT):c.296G>A (p.Arg99His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3810624"}},"detectionMethod":"Paper does not elaborate on how the mutation was discovered.","ethnicity":{"id":"cg:UnknownEthnicity"},"phenotypeFreeText":"Plasma tHcy elevation, Plasma AdoHcy elevation, at 2y 8mo AST 6x normal; ALT 3x normal; elevated plasma methionine (815, 1018, 1246, and 1247 umol/L; reference 7-47), elevated tHcy (21.4, 28.3 umol/L; reference 5-12), elevated plasma AdoMet (3348 nmol/L; reference 71-118), elevated plasma AdoHcy (63 nmol/L; reference 9.3-14.1)","phenotypes":["obo:HP_0002910","obo:HP_0003235","obo:HP_0002373"],"previousTesting":true,"previousTestingDescription":"Plasma amino acid, Plasma tHcy, AdoMet, AdoHcy measurement","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/06117e27-39d4-4676-8ebd-e7194b10e6ad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27207470","allele":{"id":"https://genegraph.clinicalgenome.org/r/3f5e7726-0197-4d48-ad2b-1563916dff08"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/06117e27-39d4-4676-8ebd-e7194b10e6ad","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06117e27-39d4-4676-8ebd-e7194b10e6ad_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/06117e27-39d4-4676-8ebd-e7194b10e6ad_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of recombinant GNMT was performed in E. coli and in HEK293 cells. In the former, the variant showed reduced solubility and activity. In the latter, the variant displayed reduced expression. Because there are ample phenotypes/variant-level evidence and the heterozygosity of the consanguineous parents has been established, this patient earns the default points.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":1.7}],"evidenceStrength":"Limited","sequence":5483,"specifiedBy":"GeneValidityCriteria9","strengthScore":6.2,"subject":{"id":"https://genegraph.clinicalgenome.org/r/HaL4tsuBON8","type":"GeneValidityProposition","disease":"obo:MONDO_0011698","gene":"hgnc:4415","modeOfInheritance":"obo:HP_0000007"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_cafb0200-f6cf-482d-9ffb-69ae7bc43669-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}